Your browser doesn't support javascript.
loading
Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2.
Swart, Maarten; van der Lubbe, Joan; Schmit-Tillemans, Sonja; van Huizen, Ella; Verspuij, Johan; Gil, Ana Izquierdo; Choi, Ying; Daal, Chenandly; Perkasa, Aditya; de Wilde, Adriaan; Claassen, Erwin; de Jong, Rineke; Wiese, Katrin E; Cornelissen, Lisette; van Es, Marieke; van Heerden, Marjolein; Kourkouta, Eleni; Tahiri, Issam; Mulders, Michel; Vreugdenhil, Jessica; Feddes-de Boer, Karin; Muchene, Leacky; Tolboom, Jeroen; Dekking, Liesbeth; Juraszek, Jarek; Vellinga, Jort; Custers, Jerome; Bos, Rinke; Schuitemaker, Hanneke; Wegmann, Frank; Roozendaal, Ramon; Kuipers, Harmjan; Zahn, Roland.
Afiliación
  • Swart M; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • van der Lubbe J; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Schmit-Tillemans S; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • van Huizen E; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Verspuij J; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Gil AI; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Choi Y; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Daal C; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Perkasa A; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • de Wilde A; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Claassen E; Wageningen Bioveterinary Research, Wageningen University & Research, Lelystad, The Netherlands.
  • de Jong R; Wageningen Bioveterinary Research, Wageningen University & Research, Lelystad, The Netherlands.
  • Wiese KE; Wageningen Bioveterinary Research, Wageningen University & Research, Lelystad, The Netherlands.
  • Cornelissen L; Wageningen Bioveterinary Research, Wageningen University & Research, Lelystad, The Netherlands.
  • van Es M; Wageningen Bioveterinary Research, Wageningen University & Research, Lelystad, The Netherlands.
  • van Heerden M; Janssen Research and Development, Preclinical Sciences and Translational Safety, Beerse, Belgium.
  • Kourkouta E; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Tahiri I; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Mulders M; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Vreugdenhil J; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Feddes-de Boer K; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Muchene L; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Tolboom J; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Dekking L; Dekking Consultancy, Leiden, The Netherlands.
  • Juraszek J; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Vellinga J; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Custers J; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Bos R; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Schuitemaker H; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Wegmann F; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Roozendaal R; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Kuipers H; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Zahn R; Janssen Vaccines & Prevention, Leiden, The Netherlands. rzahn@its.jnj.com.
NPJ Vaccines ; 8(1): 40, 2023 Mar 16.
Article en En | MEDLINE | ID: mdl-36927774
Since the original outbreak of the SARS-CoV-2 virus, several rapidly spreading SARS-CoV-2 variants of concern (VOC) have emerged. Here, we show that a single dose of Ad26.COV2.S (based on the Wuhan-Hu-1 spike variant) protects against the Gamma and Delta variants in naive hamsters, supporting the observed maintained vaccine efficacy in humans against these VOC. Adapted spike-based booster vaccines targeting Omicron variants have now been authorized in the absence of human efficacy data. We evaluated the immunogenicity and efficacy of Ad26.COV2.S.529 (encoding a stabilized Omicron BA.1 spike) in naive mice and in hamsters with pre-existing immunity to the Wuhan-Hu-1 spike. In naive mice, Ad26.COV2.S.529 elicited higher neutralizing antibody titers against SARS-CoV-2 Omicron BA.1 and BA.2, compared with Ad26.COV2.S. However, neutralizing titers against the SARS-CoV-2 B.1 (D614G) and Delta variants were lower after primary vaccination with Ad26.COV2.S.529 compared with Ad26.COV2.S. In contrast, we found comparable Omicron BA.1 and BA.2 neutralizing titers in hamsters with pre-existing Wuhan-Hu-1 spike immunity after vaccination with Ad26.COV2.S, Ad26.COV2.S.529 or a combination of the two vaccines. Moreover, all three vaccine modalities induced equivalent protection against Omicron BA.2 challenge in these animals. Overall, our data suggest that an Omicron BA.1-based booster in rodents does not improve immunogenicity and efficacy against Omicron BA.2 over an Ad26.COV2.S booster in a setting of pre-existing immunity to SARS-CoV-2.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: NPJ Vaccines Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: NPJ Vaccines Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido